Whats Next: Regulatory filing for weight management: by end of 2025 Submission for type 2 diabetes: expected in 2026 Drug discovered by Chugai, licensed by Lilly in 2018 Implication: Orforglipron could become the first once-daily oral GLP-1 therapy with potent glucose-lowering and weight-loss benefits, potentially disrupting the injectable incretin market
Hollander et al
Structural and biochemical analyses reveal the mechanism of glutathione S-transferase Pi 1 inhibition by the anti-cancer compound piperlongumine
Years of hard work and commitment have resulted in our company being recognised as the best Glutathione Tablets Manufacturer in India
Instead, Novo Nordisk offers a separate self-pay option (currently about $349 per month for the standard pen), which is a different program with its own eligibility requirements
Verhovshek, MA, CPC , is managing editor at AAPC and a member of the Asheville-Hendersonville, North Carolina, local chapter